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Abstract
Tissue-type transglutaminase (TG-2) has been implicated in
neurodegenerative diseases. In this study, induction of TG-2
was studied in rats following transient middle cerebral artery
occlusion. Alterations in 2,3,5-triphenylterazolium chloride
staining revealed maximum infarction 3 days after injury.
Measurement of mRNA transcript levels by real-time PCR
analysis showed both forms of TG-2 mRNA peaking on day 5
after injury in ipsilateral cortex, with greater induction of the
full-length TG-2 (TG-L) transcript than the truncated form of
the TG-2 (TG-S) transcript. However, in the ipsilateral hippo-
campus, peak induction of both forms of TG-2 mRNA peaked
1 day after injury and to a lesser extent than observed in the
ipsilateral cortex. Western blot analysis demonstrated that
TG-L protein expression progressively increased from 1 to
7 days after ischemia, with greater expression in cortex than
hippocampus (525 ± 10% vs. 196 ± 8% of control, respect-
ively). However, expression of TG-S was not detected. These
results demonstrate that increased TG-2 mRNA and protein
expression occurs in a delayed fashion following ischemic
injury. The temporal proﬁle of TG-2 induction after ischemia
was similar to that observed after traumatic brain injury (pre-
viously described), suggesting a similar role of TG-2 in both
pathological conditions.
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Stroke, the permanent or prolonged occlusion of an artery in
the brain, is a major cause of death and the primary cause of
adult disability in many countries. Arterial occlusion results in
tissue infarction and neuronal death (Elkind and Sacco 1998).
Thus, it is critical to develop therapeutic interventions to
amelioratethisdamage.However,themechanismsunderlying
cell loss due to cerebral ischemia remain incompletely
understood.Recentﬁndingssuggestthatmuchoftheneuronal
deathfollowingstrokeoccursasaresultofapoptosis(Mattson
2000; Graham and Chen 2001). Cerebral ischemia leads to
increased Ca
2+ inﬂux due to membrane depolarization (Kris-
tian and Siesjo 1998), resulting in the activation of proteases
(Buki et al. 2000; Beer et al. 2001) and tissue-type trans-
glutaminase (TG-2) (Lai et al.2001). These are pivotal events
in apoptotic neuronal death (Facchiano et al. 2001; Hayes
et al. 2001), in conjunction with mitochondrial dysfunction,
release of cytochrome c and increased cytokine production
(Bratton et al. 2000; Zipfel et al. 2000; Chu et al. 2002).
Tissue-type transglutaminase belongs to a family of
Ca
2+-dependent transglutaminases (TGs) that catalyses the
incorporation of a polyamine into a polypeptide-bound
glutamine, leading to the formation of an (c-glutamyl)
isopeptide bond (Greenberg et al. 1991). This isopeptide
bond is resistant to proteolytic cleavage and may serve to not
only stabilize proteins against degradation but also to alter
their function. The most ubiquitously expressed member of
the TG family is TG-2. It is abundantly expressed in the brain
(Kim et al. 1999) and is induced in cultured cells by various
agents including cytokines (Ikura et al. 1994) and cAMP
(Maddox and Haddox 1988). The most potent inducers of
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including neurons (Ferrari et al. 1998; Lefebvre et al. 1999).
Tissue-type transglutaminase has been implicated in numer-
ous processes, including axonal regeneration, cellular differ-
entiation, neurite outgrowth, apoptosis and
neurodegeneration (Suedhoff et al. 1990; Eitan and Schwartz
1993; Piredda et al. 1999; Citron et al. 2001; Tucholski
et al. 2001).
In addition to isopeptide bond formation, TG-2 has GTPase
activity (Nakaoka et al. 1994). GTP binds at the COOH-
terminal of full-length protein (Casadio et al. 1999) and
inhibits its cross-linking activity. Recently, an alternatively
spliced, short form (encoding  70 kDa protein) of TG-2
induced by cytokine treatment was produced in cultured rat
astrocytes and had greater activity at much lower Ca
2+
concentrations (Monsonego et al.1997). The short form lacks
a GTP-binding region and loss of GTPase activity correlates
with increased cross-linking activity. This loss of function
might have an impact on apoptotic neuronal death after brain
injury. For the current study, we used a model of middle
cerebral arterial occlusion (MCAO) to assess mRNA and
protein levels of these two forms of TG-2 and examined how
these changes correlated with the extent of ischemic injury.
Materials and methods
Middle cerebral artery occlusion
Transient occlusion of the right middle cerebral artery was achieved
via intraluminal occlusion with a nylon suture (He et al. 2000).
Adult male (250–300 g) Sprague-Dawley rats were anesthetized
with an abdominal injection of ketamine (60 mg/kg) and xylazine
(10 mg/kg). Core body temperature was monitored continuously by
a rectal thermistor probe and maintained at 37 ± 1 C by placing an
adjustable heating pad beneath the rats. The right common carotid
artery and right external carotid artery were exposed through a
midline neck incision. A 3-0 monoﬁlament nylon suture (25 mm
long) was inserted through an arteriotomy of the right common
carotid artery and gently advanced into the internal carotid artery to
a point approximately 17 mm distal to the carotid bifurcation. Mild
resistance to further advancement indicated that the suture had
entered the anterior cerebral artery, thereby occluding the origin of
the middle cerebral artery. After 1 h of occlusion, the nylon suture
was withdrawn and the common carotid artery was ligated. The neck
incision was closed with nylon suture. Sham-injured animals
underwent an identical surgical procedure but did not experience
occlusion. Appropriate pre- and post-injury management was
maintained and these measures complied with all guidelines set
forth by the University of Florida Institutional Animal Care and Use
Committee and the National Institutes of Health guidelines detailed
in the Guide for the Care and Use of Laboratory Animals.
Histological assessment
Staining with 2,3,5-triphenylterazolium chloride was used to assess
the extent of ischemic injury after MCAO. Following a 1-h
occlusion, animals were killed immediately (0 days) or 1, 3, 5 or
7 days after injury with CO2 and subsequently decapitated. Each
brain was removed and placed in a metallic brain matrix (Harvard
Instruments, South Natick, MA, USA) for tissue slicing. A coronal
section (2 mm thick) at the level of the optic chiasm was incubated
for 30 min at room temperature in a solution of 2% 2,3,5-
triphenylterazolium chloride in saline and then ﬁxed in 10%
formalin.
RNA puriﬁcation
Ipsilateral (side of injury) cortices and hippocampi were rapidly
dissected from animals at 1–7 days after occlusion and from sham-
injured animals on day 5. At the appropriate time-points, animals
were killed with CO2 and subsequently decapitated. Total RNA was
isolated using TRIzol reagent (Gibco BRL, Rockville, MD, USA).
Isopropanol precipitation and ethanol washes were performed
according to the manufacturer’s instructions and samples were
resuspended in 50–100 lL DEPC-treated water.
Reverse transcription
Total RNA (3 lg) was incubated with 1 lL oligo(dT) (0.5 mg/mL;
GibcoBRL) at 70 C for 10 min and then at 4 C for 5 min. A RT
reaction mixture was added to the RNA-oligo(dT) sample for a ﬁnal
volume of 20 lL, containing 20 mM Tris-HCl (pH 8.4), 50 mM
KCl, 5 mM MgCl2, 500 lM dNTPs, 10 mM dithiothreitol, 50 units
SuperScript II reverse transcriptase (GibcoBRL) and 40 units
RNaseOUT recombinant ribonuclease inhibitor (GibcoBRL). The
sample was incubated at 42 C for 55 min, 70 C for 15 min for
enzyme denaturation and then transferred to 4 C. Each sample was
diluted to a ﬁnal volume of 100 lL with DEPC-treated water.
Primer selection
Tissue-type transglutaminase-speciﬁc primers
All base pair designations refer to GeneBank locus AF106325, rat
TG-2. 5¢TG (ACTTTGACGTGTTTGCCCAC, bp 1470–1489)
recognizes an upstream homologous sequence in full-length TG-2
(TG-L) and truncated TG-2 (TG-S) transcripts. 3¢TG-L (CAAT-
ATCAGTCGGGAACAGGTC, bp 1961–1982) recognizes a down-
stream TG-L mRNA-speciﬁc sequence. 3¢TG-S (GCTGAGTCTGG,
GTGAAGACACAG, bp 1861–1872 and 2083–2093) recognizes a
downstream TG-S mRNA-speciﬁc sequence. 3¢TG-S primer bridges
the junction created by the absence of bp 1873–2082 (a sequence
present exclusively in TG-L). The underlined 3¢ half of the 3¢TG-S
sequence will hybridize to both the TG-L- and TG-S-speciﬁc
sequences while the full-length primer will hybridize only to the
TG-S mRNA sequence.
GAPDH-speciﬁc primers
All base pair designations for GAPDH-speciﬁc primers refer to
GeneBank locus AF106860. The upstream primer is designated
5¢GPD (GGCTGCCTTCTCTTGTGAC, bp 903–921) and the
downstream primer is designated 3¢GPD (GGCCGCCTGCTTCAC-
CAC, bp 1624–1641).
Semi-quantitative/light cycler PCR
Real-time PCR was performed using a Light Cycler rapid thermal
cycler system (Roche Diagnostics, Indianapolis, IN, USA), as
previously described (Tolentino et al. 2002). Reactions were
performed in a 10-lL volume with 0.5 lM primers and 2.5 mM
MgCl2. Other reagents, including nucleotides, Fast Start Taq DNA
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Cycler-FastStart DNA Master SYBR Green I reaction mix
(Roche Diagnostics). The ampliﬁcation protocol included a 5-min
95 C denaturation; one cycle with 95 C denaturation for 5 s, 65 C
annealing for 10 s and 72 C extension for 35 s; one cycle with 95 C
denaturation for 5 s, 62.5 C annealing for 10 s and 72 C extension
for 35 s and then 30–40 cycles of 95 C denaturation for 5 s, 60 C
annealing for 10 s and 72 C extension for 35 s. Detection of the
ﬂuorescent product occurred at the end of the 72 C extension
periods. Speciﬁcity of the ampliﬁcation product from each primer
pair was conﬁrmed by melting curve analysis of the PCR product
and subsequent gel electrophoresis.
Quantiﬁcation was performed by online monitoring for identiﬁ-
cation of the exact time-point at which the logarithmic linear phase
could be distinguished from the background (crossing point). The
crossing point is expressed as a cycle number.
Standard curve preparation and semiquantitative PCR analysis
The RT product from ipsilateral cortical RNA collected 3 days
(when the initial mRNA induction was observed) after ischemic
injury underwent serial dilution creating a standard curve of 100, 33,
11 and 3.7% of original real-time product. Each dilution from the
standard curve was analyzed with the Light Cycler PCR using
primer sets for TG-L, TG-S or GAPDH mRNA. For each primer set,
a crossing point cycle number was determined for each dilution of
the standard curve. Linear regression analysis of the logarithm of the
dilution factor versus the crossing point cycle number generated a
standard curve for each transcript-speciﬁc primer set. From the
standard curve of each primer set, a crossing point cycle number
could be converted to a relative amount of RNA. For individual
samples, the crossing point cycle number was identiﬁed with the
Light Cycler PCR. Using the standard curve for each primer set, the
amount of TG-L, TG-S or GAPDH mRNA was determined.
The amount of each transcript in sham animals was set at 100%
and the level of expression in an occluded sample was calculated as
a percent of sham expression.
Tissue lysis and protein puriﬁcation
Cortical and hippocampal tissues were collected from animals
1–7 days after ischemic injury and from sham-injured animals
5 days after injury. At the appropriate time-points, animals were
killed by CO2 and subsequent decapitation. Ipsilateral and
contralateral cortices and hippocampi were rapidly dissected and
snap-frozen in liquid nitrogen. Tissue samples were stored at
)80 C. Tissues were homogenized in a glass tube with a Teﬂon
dounce pestle in 15 volumes of ice-cold triple detergent lysis
buffer [20 mM Hepes, 1 mM EDTA, 2 mM EGTA, 150 mM NaCl,
0.1% sodium dodeyl sulfate, 1.0% IGEPAL 40 and 0.5%
deoxycholic acid, pH 7.5] containing a broad-range protease
inhibitor cocktail (Roche Molecular Biochemicals, Indianapolis,
IN, USA). Samples were sonicated and centrifuged at 800 g for
5 min at 4 C. The supernatant ﬂuid was then collected for
western blot analysis.
Western blot analysis
Protein concentrations of tissue homogenates were determined by
bicinchoninic acid microprotein assays (Pierce, Rockford, IL,
USA) cwith albumin standards. Aliquots (20 lg) of each sample
were prepared for sodium dodeyl sulfate–polyacrylamide gel
electrophoresis by the addition of 2· loading buffer [1· loading
buffer contains 125 mM Tris-HCl (pH 6.8), 100 mM dithiothreitol,
4% sodium dodeyl sulfate, 0.01% bromophenol blue and 10%
glycerol]. Samples with loading buffer were heated for 10 min at
100 C, centrifuged for 1 min at 10 000 g and resolved by sodium
dodeyl sulfate–polyacrylamide gel electrophoresis on 7.5% Tris/
glycine gels at 200 V for 1 h at 4 C. Following electrophoresis,
fractionated proteins were transferred to Immobilon-P polyvinylid-
ene ﬂuoride membrane (Millipore Corporation, Bedford, MA, USA)
in a transfer buffer containing 192 mM glycine, 25 mM Tris-HCl
(pH 8.3) and 10% methanol at 100 V for 1 h at 4 C. Blots were
blocked for 1 h at room temperature in 5% non-fat milk in TBST
(20 mM Tris-HCl, 150 mM NaCl and 0.005% Tween-20, pH 7.5).
Immunoblots were probed with TG-100, a monoclonal anti-TG-2
antibody (LabVision, Fremont, CA, USA). Following overnight
incubation at 4 C with the primary antibody (1 : 3000), blots were
incubated for 1 h at room temperature in 3% non-fat milk/TBST
containing a horseradish peroxidase-conjugated goat anti-mouse
IgG (1 : 3000; Bio-Rad Laboratories, Hercules, CA, USA). Bound
antibodies were visualized with enhanced chemiluminescence
(Amersham Pharmacia Biotech, Piscataway, NJ, USA) on Kodak
Biomax ML chemiluminescent ﬁlm (Fisher Scientiﬁc International
Inc., Hampton, NH, USA).
Statistical analyses
For the western blots, semiquantitative analysis was performed by
computer-assisted densitometric scanning (Alpha Imager 2000
Digital Imaging System, Alpha Innotech Corporation, San Leandro,
CA, USA). For each time-point studied, n ¼ 4 per group. Data were
acquired as integrated densitometric values and transformed to
percentages of the densitometric levels obtained from sham-injured
animals visualized on the same blot. Data were evaluated by two-
tailed Student’s t-test. All values are given as mean ±SEM.
Differences were considered signiﬁcant if p < 0.05.
Results
Histological assessment of ischemic injury
Coronal sections of rat brain (2 mm thick) were collected
immediately to 7 days after transient MCAO and stained
with 2,3,5-triphenylterazolium chloride (Fig. 1). Decreased
2,3,5-triphenylterazolium chloride staining was noted in
areas of infarction. The maximal effect of occlusion was
noted 3 days after ischemic injury, with a smaller infarct
revealed at later time-points.
PCR analysis of tissue-type transglutaminase transcripts
A previous report described the use of a semiquantitative
PCR analysis to measure the expression of TG-L and TG-S
mRNA in rat cortex and hippocampus after traumatic brain
injury (Tolentino et al. 2002). The same technique was used
to measure the expression of these transcripts in rat cortex
and hippocampus after ischemic injury. Figure 2 shows the
time-course of TG-L and TG-S mRNA expression in
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ipsilateral cortex, maximal and signiﬁcantly elevated expres-
sion of TG-L and TG-S mRNA was observed 5 days after
injury (990 ± 130% and 690 ± 90% of control, respect-
ively). In the hippocampus, maximal and signiﬁcantly
elevated TG-L and TG-S mRNA levels were observed
1 day after injury (200 ± 20% and 175 ± 11% of control,
respectively).
Western blot analysis of cortical tissue-type
transglutaminase expression after ischemic injury
Total protein was prepared from ipsilateral and contralateral
rat cortex after sham and ischemic injury. Figure 3(a) shows
TG-2 protein expression in rat cortex 1–7 days after ischemic
injury. Using the TG-100 (monoclonal anti-TG-2) antibody, a
distinct TG-2 protein band at  79 kDa was identiﬁed,
corresponding to TG-L. However, TG-S ( 70 kDa) was not
identiﬁed using this antibody. The expression of TG-L was
increased in a time-dependent manner compared with the
sham-injured control. Western blot data were quantiﬁed by
densitometric analysis (Fig. 3b). Levels of TG-L expression
were calculated as a percent of the sham control. The
induction of TG-L was observed 3–7 days after cortical
occlusion with maximum induction on day 7 (525 ± 10% of
control). Comparing expression between matched ipsilateral
and contralateral cortical tissues, statistically signiﬁcant
elevated expression was observed at 3, 5 and 7 days.
Contralateral samples that showed no change in TG-2
expression were used as equal loading controls.
Fig. 1 2,3,5 -Triphenylterazolium chloride staining of rat brain coronal sections after ischemic injury. 1–7 days after transient right middle cerebral
arterial occlusion, rat brains were dissected and sectioned in the coronal plane. Areas of infarcted tissue were revealed by decreased staining.
Maximal effect of occlusion was noted 3 days after injury with a smaller infarct revealed at later time-points.
Fig. 2 Semi-quantitative PCR analysis of TG-L and TG-S mRNA
expression in ipsilateral cortex (a) and hippocampus (b). TG-L (r)a n d
TG-S (j) mRNA levels were calculated as a percent of sham (Sh)
control. In cortex, maximal TG-L and TG-S mRNA expression was
noted 5 days after ischemia while, in hippocampus, maximal expres-
sion was noted 1 day after ischemia (*p <0 Æ05).
(a)
(b)
Fig. 3 (a) A representative western blot showing TG-2 expression in
cortical protein samples using the anti-TG-2 antibody (TG-100).
Samples were collected from injured animals 1, 3, 5 and 7 days after
ischemic injury and from sham-injured (Sh) animals. TG-L (79 kDa)
expression was increased in a time-dependent manner, while TG-S
(70 kDa), was not identiﬁed in these samples, even at longer expo-
sures. The TG-L protein expression in contralateral (Contra) samples
remained the same. (b) Data from multiple (n ¼ 3) western blots were
acquired as densitometric values and transformed to percentages of
the densitometric values obtained from control samples (sham-injured
animals). Quantitative analysis of western blots showed increases in
protein level following injury in a time-dependent manner on days 3, 5
and 7 compared with control animals (Sh). Comparing TG-L expres-
sion from ipsilateral (Ipsi) and contralateral cortex at each time-point,
increased levels of expression were statistically signiﬁcant at 3–7 days
in the ipsilateral cortex (*p<0.05, **p<0.005).
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transglutaminase expression after ischemic injury
Total protein was prepared from ipsilateral and contralateral
rat hippocampus after ischemic and sham injury and the
expression of TG-2 was examined using TG-100. Figure 4(a)
shows TG-2 protein expression in rat hippocampus 1–7 days
after ischemic injury. Similar to western blot analyses of
cortical samples, only TG-L ( 79 kDa) was identiﬁed. The
expression of TG-L protein was increased in a time-
dependent manner from days 3 to 7 compared with the
sham control. However, the induction level was lower than in
ipsilateral cortex. Quantitative densitometric analysis
(Fig. 4b) revealed maximum expression at 7 days after
injury (196 ± 8%). Comparing expression between matched
ipsilateral and contralateral hippocampal tissues, statistically
signiﬁcant elevated expression was observed at 3, 5 and
7 days after injury. Contralateral samples that showed no
change in TG-2 expression were used as equal loading
controls.
Discussion
The TG family has been studied in a variety of injury models.
The current study provides the ﬁrst evidence of TG-2
induction in response to cerebral ischemia in a trend similar
to that observed after traumatic brain injury (Tolentino et al.
2002), suggesting that TG-2 may be a good predictor for the
pathophysiology accompanying traumatic and ischemic brain
injury. Moreover, in a model of spinal cord ischemia, TG
activity underwent a transient increase that declined to
control levels after 1 week (Fujita et al. 1995). The TG-2
protein and transcript expression were observed after spinal
cord injury and both the short- and long-form transcripts
were identiﬁed after injury (Festoff et al. 2002). In the
superior cervical ganglion, TG activity was increased within
1 h of axotomy and returned to baseline after 24 h (Gilad
et al. 1985; Ando et al. 1993). The TG activity also
increased in the vagus nerve after crush injury (Tetzlaff
et al. 1988).
The role of TG-2 induction in the neural response to injury
is not well understood; however, based on other experimental
injury models, both damaging and protective functions can
be proposed. For example, exogenous application of TG to
injured optic nerve promoted axonal regeneration and
recovery of visual-evoked responses (Eitan et al. 1994). In
SH-SY5Y neuroblastoma cells, TG-2 stimulated neuronal
differentiation (Tucholski et al. 2001). It was proposed that
the supportive effects of TG treatment were due to stabil-
ization of matrix proteins or protection of growing axons
from oligodendrocyte-mediated growth inhibition. It had
been previously shown that TG dimerizes interleukin-2 and
that interleukin-2 dimers were cytotoxic to cultured oligo-
dendrocytes (Eitan and Schwartz 1993).
Several studies have demonstrated the dual role of TG-2 in
neuronal life and death processes (Im et al. 1997; Gill et al.
1998; Casadio et al. 1999). Increase in the TG-S transcript
predicts production of a more active enzyme. As GTP is
inhibitory to the cross-linking activity of TG-2, loss of this
region presumably results in a switch of TG-2 function to
programmed cell death with increases in cross-linking and
production of aggregated proteins (Norlund et al. 1999;
Citron et al. 2001, 2002). Our studies have demonstrated an
increased message level of TG-S after MCAO; however, its
protein expression was not detected, suggesting that TG-S
protein may be expressed at an undetectable level. However,
TG-S protein expression was recently detected in the spinal
cord injury model by using a different set of antibodies
(Festoff et al. 2002). Apoptotic neuronal death has been
widely documented after ischemic brain injury (Mattson
2000; Graham and Chen 2001) and induction of TG-S mRNA
expression may increase apoptotic neuronal death and cross-
linking activity. Further understanding of the regulation of
TG-2 transcription may provide additional opportunities to
control TG-2 expression as a potential therapy against
(a)
(b)
Fig. 4 (a) A representative western blot showing TG-2 expression in
hippocampal protein samples using the anti-TG-2 antibody (TG-100).
Samples were collected from 1, 3, 5 and 7 days after ischemic injury
and sham-injured animals. TG-L (79 kDa) protein expression
increased in a time-dependent manner compared to sham-injured
controls, while TG-S (70 kDa) was not identiﬁed, even with longer
exposure time. (b) Data from multiple (n ¼ 3) western blots were ac-
quired as densitometric values and transformed to percentages of the
densitometric values obtained from control samples (sham-injured
animals). Quantitative analysis of western blots showed increases in
protein level following injury in a time-dependent manner on days 3, 5
and 7 compared with control animals (Sh). Comparing TG-L expres-
sion from ipsilateral (Ipsi HC) and contralateral (Cont HC) at each
time-point, increased levels of expression were statistically signiﬁcant
at 3–7 days in ipsilateral hippocampus (*p<0.05, **p<0.005).
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lead to neurodegenerative diseases. In addition, the cell type
localization and pathophysiology of TG-2 induction bear
further examination. Tissue-type transglutaminase may be
important not only for subsequent cell death after brain injury
but also for compensatory mechanisms of other brain systems
as they respond to the injury.
Tissue-type transglutaminase expression has been impli-
cated in the cellular pathogenesis of Alzheimer’s disease
(AD) (Lesort et al. 2000; Citron et al. 2001) and increased
TG-2 mRNA, protein expression and TGase activity have
been observed in brains of AD and Parkinson’s disease
patients compared with controls (Citron et al. 2001, 2002).
The TG-S isoform message was absent in normal brains but
present in AD patients and accompanied by an increase in
cross-linking of disease-speciﬁc proteins, such as tau and
a-synuclein (Citron et al. 2002). If TG activity is physio-
logically relevant to the development of AD, then TG
induction after MCAO may contribute to the epidemiological
observation that a subset of individuals who experience
ischemia are at a greater risk of developing AD. Recent
advances suggest that cerebral ischemia may promote AD
(Kalaria 2000). The underlying pathophysiological mecha-
nisms of AD and stroke are similar (Blass and Ratan 2003).
Cerebral ischemia may promote AD by triggering the
development of senile plaques and neuroﬁbrillary tangles
(Vermeer et al. 2003). Further, MCAO increases the expres-
sion of presenilin, amyloid precursor protein (APP) and
Apolipoprotein E (APE) (Pennypacker et al. 1999; Pluta
2000). These studies suggest that cerebral ischemia may
cause cellular and molecular events that have neurodegen-
erative consequences and subsequently lead to the devel-
opment of AD (Pennypacker et al. 1999; Kalaria 2000; Pluta
2000; Blass and Ratan 2003; Vermeer et al. 2003). The
induction of both AD-related proteins and TG-2 following
brain injury provides a potential mechanism by which
cerebral ischemia may contribute to AD pathology. This
hypothesis awaits further in vivo and in vitro experiment.
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